SHAREHOLDER ALERT: BIRD FULC SPR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / May 22, 2023 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Allbirds, Inc. (NASDAQ:BIRD)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/allbirds-class-action-submission-form?prid=39706&wire=1
Lead Plaintiff Deadline: June 12, 2023
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Allbirds Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's November 2021 initial public offering; and/or (b) Allbirds securities between November 4, 2021 and March 9, 2023, inclusive.

Allegations against BIRD include that: (1) Allbirds was overemphasizing products that extended beyond the Company's core offerings; (2) the Company's non-core products had a narrower appeal and were not resonating with customers as well as the Company's core products; (3) Allbirds was underinvesting in its core consumers' favorite products to push the Company's newer products with narrower appeal; (4) underinvesting in Allbirds' core products was negatively impacting the Company's sales; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fulcrum-class-action-submission-form?prid=39706&wire=1
Lead Plaintiff Deadline: June 27, 2023
Class Period: March 3, 2022 - March 8, 2023

Allegations against FULC include that: (i) the preclinical data submitted in support of FTX-6058 (an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies) showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Spirit AeroSystems Holdings, Inc. (NYSE:SPR)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spirit-class-action-submission-form?prid=39706&wire=1
Lead Plaintiff Deadline: July 5, 2023
Class Period: April 8, 2020 - April 13, 2023

Allegations against SPR include that: (1) Spirit lacked effective production quality controls; (2) as a result, Spirit incorrectly installed fittings designed to join the aft fuselage to the vertical tail for some Boeing 737 Max airplanes that Spirit sent to Boeing; (3) as a result, Spirit would have to develop an inspection and repair procedure for the affected fuselages; (4) the foregoing would negatively impact Spirit's financial results; and (5) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.